Sledování nákladné pneumoonkologické léčby pokročilého nemalobuněčného karcinomu plic v první linii v registru TULUNG v České republice (stav k 15.3.2017)

Follow-up of costly pneumooncological treatment of advanced NSCLC with first-line treatment according to the TULUNG registry in the Czech Republic (up to March 15, 2017)

SKŘIČKOVÁ, Jana (203 Czech Republic, guarantor, belonging to the institution), Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Marek KONEČNÝ (203 Czech Republic), Milan PEŠEK (203 Czech Republic), Petr ZATLOUKAL (203 Czech Republic), Vítězslav KOLEK (203 Czech Republic), František SALAJKA (203 Czech Republic), Michal HRNČIARIK (203 Czech Republic), Leona KOUBKOVÁ (203 Czech Republic), Marcela TOMÍŠKOVÁ (203 Czech Republic, belonging to the institution), Yvona GRYGÁRKOVÁ (203 Czech Republic), Libor HAVEL (203 Czech Republic), Milada ZEMANOVÁ (203 Czech Republic), dimka SIXTOVÁ (203 Czech Republic), Jaromír ROUBEC (203 Czech Republic), Leona ČOUPKOVÁ (203 Czech Republic), Markéta ČERNOVSKÁ (203 Czech Republic), Petr OPÁLKA (203 Czech Republic), Jana KREJČÍ (203 Czech Republic), Monika ŠATÁNKOVÁ (203 Czech Republic, belonging to the institution), Andrea BENEJOVÁ (703 Slovakia, belonging to the institution), Miroslav MAREL (203 Czech Republic) and Martina VAŠÁKOVÁ (203 Czech Republic)

Praha, Farmakoterapie, p. 8-12, 5 pp. 2017

Farmakon Press

Czech

Popularizační texty a aktivity

30203 Respiratory systems

Czech Republic

není předmětem státního či obchodního tajemství

RIV/00216224:14110/17:00098649

Faculty of Medicine

non-small cell lung cancer (NSCLC); pemetrexed; erlotinib; bevacizumab; gefinitib; afatinib;TULUNG registry

Reviewed